Holtorf, AP. (2013) “PATIENT REPORTED OUTCOMES.” In Pharmacoeconomics. Principles and Practice. Chapter 5. Torino, Italy: SEEd srl, First edition. ISBN: 978-88-9741-938-9.
E Faulkner, L Annemans, L Garrison, M Helfand, AP Holtorf, J Hornberger, D Hughes, et al. “Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group.” Value Health 15, 1162–1171 (2012).
Anke-Peggy Holtorf, Diana Brixner, Brandon Bellows, and Abdulkadir Keskinaslan. “Current and Future Use of HEOR Data in Decision making in the US and Emerging Markets.” American Health & Drug Benefits, 5/7, 428–438; (2012).
Biskupiak JE, Dunn JD, Holtorf A-P. Implementing CER: What Will It Take? J Manag Care Pharm. 2012;18(5 Supp A):S19–29.
Holtorf, A.P., H. Rinde, and N. Maniadakis. “PHP142 Drug Shortages Around the World and the Underlying Reasons.” Value in Health 15, no. 7 (November 2012): A314.
Faulkner, Eric C, AP Holtorf, M Longacre, and Lieven Annemans. 2011. Value-Based Reimbursement For Personalized Medicine: Where Do We Stand? ‘Value in Health‘. Madrid, Spain, November.
Holtorf, A P, Gary Oderda, Andres Pichon-Riviere, and Abdulkadir Keskinaslan. 2011. The Role Of Health Economic And Outcomes Research (Heor) Evidence In Formulary And Reimbursement Decisions In Latin America Versus The United States. In Value in Health. Vol. 7. Mexico City, September.
Holtorf, A-P, A Keskinaslan, JE Biskupiak, and DI Brixner. 2010. Current and Future Use of Pharmacoeconomic and Outcomes Research Data in Decision Making in the USA. Poster presented at the ISPOR 13th Annaual European Meeting, November, Prague.
A.P.Holtorf, D. Brixner, J. Biskupiak. Current and future use of health economic and outcomes research data in decision making. Workshop. ESMDM Meeting, Hall, Austria, 31.May-2.June 2010
Brixner DI, Holtorf A, Neumann PJ, Malone DC, & Watkins JB (2009) Standardizing quality assessment of observational studies for decision making in health care. J Manag Care Pharm 15:275-83.
Szeinbach, Sheryl L, Noreen Sullivan, Enrique Seoane-Vazquez, Amit Chhabra, Eric Faulkner, Anke-Peggy Holtorf, Dimitri Polygenis, Mayvis Rebeira, Jose Manuel Rodriguez, and Karl Matuszewski. “Identifying Key Decision Pathways in Health Technology Assessment Around the World.” Orlando, 2009.
Holtorf A, McAdam-Marx C, Schaaf D, Eng B, & Oderda G (2009) Systematic review on quality control for drug management programs: Is quality reported in the literature? BMC Health Services Research 9:38.
Diana Brixner RPh, PhD, Daniel Malone PhD, RPh, Anke-Peggy Holtorf PhD, MBA. Use of Real World Data Workshop: Quality assurance of evidence from real world data (RWD) for reimbursement decisions. ISPOR International Congress, Paris 2009.
A.-P. Holtorf (2008) Health Technology Assessment and Decision making in the USA. Invited lecture. 14th International Pharmaceutical Technology Symposium (IPTS). Antalya, Turkey
C McAdam-Marx, DT Schaaf, AP Holtorf, Benjamin Eng, GM. Oderda. Systematic Analysis of Outcomes Evaluations Applied to Drug Management Programs. Am J Manag Care. 2008;14(11 Spec No.):SP36-SP45.
Holtorf A, Watkins JB, Mullins CD, Brixner D. Incorporating Observational Data into the Formulary Decision-Making Process—Summary of a Roundtable Discussion. J Manag Care Pharm. 2008;14(3):302-8.
Nickman NA, Haak SW, Harald E, Holtorf A, Joshi A, Kim J, et al. Cost Minimization Analysis of Different Growth Hormone Devices Based on Time-And-Motion Simulations. In: Value in Health. 2008. Poster at ISPOR 13th Annual International Meeting, May 3-7, Toronto
A-P. Holtorf; J. LaFleur; D. Servatius; B. Jeffries; D. Brixner, (2007) Prescription Drug Use by Women and Men in Utah Medicaid. UTAH’S HEALTH: An Annual Review, Volume 12: Supplement: Women’s Health in Utah, pp 97-99, Eds.: National Center of Excellence In Women’s Health Demonstration Project Region VIII.
Nickman N, Haak SW, Holtorf AP, Joshi AV, Brixner D (2007) Time-And-Motion Evaluation of Different Growth Hormone Formulations. Poster presentation at ISPOR 10th Annual European Congress in Dublin; Sunday, 21 October 2007.
A-P. Holtorf, J. LaFleur, D. Servatius, B. Jeffries, C. McBeth, D. Brixner, (2007) Statin Treatment of Diabetic Patients in Utah Medicaid. UTAH’S HEALTH: An Annual Review, Volume 12: Supplement: Women’s Health in Utah, pp 57-71, Eds.: National Center of Excellence In Women’s Health Demonstration Project Region VIII.
A-P. Holtorf, PhD, MBA; J. LaFleur, PharmD, MSPH; D. Servatius; B. Jeffries, PharmD Candidate; D. Brixner, RPh, PhD, (2007) Prescription Drug Use in Utah Medicaid. Utah Health Services Research Conference: “Utah Health Services Research Meets Public Health Informatics”, University of Utah, Salt Lake City (Poster).
A-P. Holtorf, J. LaFleur, D. Servatius, B. Jeffries, C. McBeth, D. Brixner, (2007) Statin Treatment of Diabetic Patients in Utah Medicaid. Utah Health Services Research Conference: “Utah Health Services Research Meets Public Health Informatics”, University of Utah, Salt Lake City (Poster).
Wasserfallen, Jean-Blaise; Synove, Daneel; Rinde, Harald; Forster, Adrian. “Changes of Working Ability and Handicap in a Swiss Cohort of Rheumatoid Arthritis Patients Treated with Etanercept in Daily Practice” [3rd Annual Meeting of Health Technology Assessment International (HTAi), an international society for the promotion of health technology assessment 2006. Published in: International Journal of Technology Assessment in Health Care (IJTAHC)] Jul-2006.
Wasserfallen, Jean-Blaise; Synove, Daneel; Rinde, Harald; Forster, Adrian. “Efficacy of Etanercept in Daily Clinical Practice in Swiss Cohort of Rheumatoid Arthritis Patients” [3rd Annual Meeting of Health Technology Assessment International (HTAi), an international society for the promotion of health technology assessment] Jul-2006.
John G. Thomas, Isaiah Litton, Harald Rinde. “Chapter 2: Economic Impact of Biofilms on Treatment Cost” Chapter 2: Editors: John L. Pace, Mark E. Rupp, Roger G. Finch. [Biofilms, Infection and Antimicrobial Therapy. Taylor & Frances. ISBN: 9780824726430] 2006.
Harald Rinde, Adrian Forster, Synove Daneel, J-B. Wasserfallen, Amitabh Singh, Jorge Wernli. “Etanercept Demonstrated Significant Reduction of Burden of Illness After 3 Years of Treatment in Swiss Moderate to Severe RA Cohort”. [Association of Rheumatology Health Professionals Annual Scientific Meeting, San Antonio] Oct-2004.
A Singh, H Rinde, A Forster, S Daneel, J-B Wasserfallen, J Wernli. “Work and Productivity Loss in a Swiss Cohort of Patients with Moderate to Severe RA: Results from Swiss Clinical Quality Management Study”. [American College of Rheumatology / Association of Rheumatology Health Proffessionals (ACR/ARHP) Annual Scientific Meeting] 2004.
Karl Klingler, Jurg Barandun, Thomas Scherer, Beat Walder, Harald Rinde and Jorge Wernli. “A Double-Bind Randomized, Placebo-Controlled Trial for Smoking Reduction Involving Nicotine Replacement Therapy (NRT)”. [75th anniversary of the Congress of Swiss Pneumologists in St. Gallen, Switzerland. 12th World Conference on Tobacco or Health in Helsinki August 3-8, 2003].
A.-P. Holtorf, D. Brixner (1996) Separating Fact from Fantasy, Jan. 22-24, 1996, Tucson, Arizona – Panel Discussion.